BioMaxima

BioMaxima Debt Growth

The Year-over-Year Debt Growth of BioMaxima (BMX.WA) as of Oct 16, 2026 is -1.12 %. In the previous year, Year-over-Year Debt Growth was 13.67 % — a change of -108.21% (lower).

Debt Growth

-1.12 %

YoY

-108.21%

Last updated:

Year-over-Year Debt Growth of BioMaxima is 2025 -1.12 % . Year-over-Year Debt Growth of BioMaxima was 2024 13.67 % . It decreases by -108.21% lower compared to the previous year.

The BioMaxima Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2018
215.30 PLN
Jan 1, 2019
-23.09 PLN
Jan 1, 2020
2.50 PLN
Jan 1, 2021
38.88 PLN
Jan 1, 2022
-66.26 PLN
Jan 1, 2023
120.68 PLN
Jan 1, 2024
13.67 PLN
Jan 1, 2025
-1.12 PLN
The BioMaxima Debt Growth history
YEARDebt GrowthYoY
-1.12 %-108.21%
13.67 %-88.67%
120.68 %-282.14%
-66.26 %-270.41%
38.88 %+1,452.16%
2.50 %-110.85%
-23.09 %-110.72%
215.30 %+502.17%
35.75 %-476.07%
-9.51 %-49.21%
-18.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioMaxima Stock analysis

What does BioMaxima do? BioMaxima SA is a company based in Lublin, Poland, operating within the Health Care sector, specifically in the Health Care industry. The company went public via an IPO on June 8, 2010, and is listed under the ticker BMX.WA with ISIN PLBIOMX00015. BioMaxima SA specializes in biotechnology and laboratory diagnostics, manufacturing and distributing reagents and equipment for laboratory diagnosis. The company produces in vitro diagnostic reagents and offers a range of products including diagnostic reagents and analyzers for clinical biochemistry, rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers, and drugs of abuse, urine analysis systems, hematology analyzers and reagents, ion-selective analyzers and reagents, reagents and immunological analyzers for cardiac markers, glucometers, and analyzers for gasometric and critical blood parameters tests. BioMaxima SA supplies hospitals and laboratories across Poland, Lithuania, Latvia, Romania, and France. The company merged with its wholly owned subsidiary Cebo Sp z o o on March 20, 2014. The company's website is https://biomaxima.com/. BioMaxima is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioMaxima stock

Year-over-Year Debt Growth of BioMaxima is -1.12 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth BioMaxima since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's BioMaxima historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — BioMaxima

All Key Metrics — BioMaxima